425: ARCA Biopharma to Merge with Oruka Therapeutics, Creating New Inflammatory Skin Disease Leader

ARCA Biopharma is set to merge with Oruka Therapeutics, a company focused on developing best-in-class therapies for psoriasis and other inflammatory skin diseases, with a concurrent $275 million PIPE financing.

Summary

• ARCA Biopharma is merging with Oruka Therapeutics in a reverse-triangle merger, with Oruka surviving as a wholly-owned subsidiary of ARCA.
• Post-closing, ARCA will be renamed Oruka Therapeutics, Inc.
• Oruka holders will own approximately 97.6% of the combined enterprise, while ARCA holders will own about 2.4%.
• The transaction includes a concurrent private investment (PIPE) of $275 million, led by Fairmount.
• The closing is expected to occur during the third quarter of 2024.
• The combined company will focus on developing therapies for inflammatory skin diseases, particularly psoriasis, with lead programs targeting a $50B+ total market opportunity.
• Oruka's pipeline includes ORKA-001 (anti-IL-23) and ORKA-002 (anti-IL-17A/F), both potentially best-in-class.
• A single fundraise of $275M could support multiple inflection points through 2027.

Sentiment

Score: 8

Explanation: The document presents a positive outlook due to the merger, substantial PIPE financing, and promising pipeline assets targeting a large market. The potential for best-in-class therapies and a catalyst-rich development path further contribute to the positive sentiment.

Positives

• Merger creates a company focused on a large and growing market for inflammatory skin disease therapies.
• Oruka's pipeline includes potentially best-in-class assets with novel IP into the 2040s.
• The $275 million PIPE financing provides substantial capital to advance the pipeline.
• ORKA-001 has the potential for less frequent dosing (1-2 times per year) compared to existing therapies.
• ORKA-002 targets a $15B market and has the potential to be best-in-class.
• The development path is expected to be catalyst-rich over the next 3 years.
• The company has backing from Paragon and Fairmount.

Negatives

• The merger is subject to customary closing conditions, including regulatory approvals and stockholder approvals.
• The success of the combined company depends on the successful development and commercialization of Oruka's pipeline assets, which is subject to clinical and regulatory risks.
• The company will face competition from existing therapies and other companies developing treatments for inflammatory skin diseases.
• The company is reliant on a single fundraise to support multiple inflection points.

Risks

• Clinical trial failures or delays could negatively impact the development of Oruka's pipeline assets.
• Regulatory hurdles and potential delays in obtaining approvals for new therapies.
• Competition from established players in the inflammatory skin disease market.
• The company's ability to protect its intellectual property.
• The risk that the PIPE financing may not close as expected.
• The company's ability to successfully integrate ARCA and Oruka operations.

Future Outlook

The combined company will focus on developing and commercializing novel therapies for inflammatory skin diseases, with a catalyst-rich development path expected over the next three years. The company anticipates multiple inflection points, including clinical trial readouts and potential regulatory submissions.

Industry Context

The merger reflects a growing trend in the pharmaceutical industry towards specialization and focus on specific therapeutic areas. The inflammatory skin disease market is highly competitive, with several large pharmaceutical companies and emerging biotech firms vying for market share. Dual IL-17A/F inhibition has shown superior efficacy vs. IL-17A inhibition, with $15B+ in future market potential.

Comparison to Industry Standards

• ORKA-001 is being developed as a potentially best-in-class anti-IL-23, similar to Skyrizi (risankizumab) but with the potential for less frequent dosing.
• ORKA-002 is being developed as a potentially best-in-class anti-IL-17A/F, similar to Bimzelx (bimekizumab) but with a potentially improved product profile.
• The KNOCKOUT study tested higher anti-IL-23 exposures in PsO using Skyrizi at 2-4x the approved dose.
• Bimzelx is showing signs of massive peak sales potential.
• The average time from FIH to BLA/NDA is 6.5 years.

Stakeholder Impact

• Shareholders of ARCA and Oruka will be impacted by the merger and the resulting ownership structure.
• Employees of both companies will be affected by the integration of operations.
• Patients with inflammatory skin diseases could benefit from the development of new and improved therapies.
• The transaction could create value for investors in the combined company.

Next Steps

• File Form S-4 with the SEC.
• Obtain stockholder approvals from both ARCA and Oruka.
• Close the merger, expected in the third quarter of 2024.
• Advance the clinical development of ORKA-001 and ORKA-002.
• File Resale registration statement covering Oruka affiliates promptly post-closing.

Key Dates